Astra Zeneca and Merck partner on drug regimen

July 23, 2009

AstraZeneca and Merck & Co. have formed an alliance to research the combination of two investigational compounds: AZD6244 (ARRY-886) from AstraZeneca and MK-2206 from Merck. They will work together on a phase I trial and share the costs of the research.

AZD6244 blocks the MEK pathway and is currently under investigation in skin, colorectal, and lung cancers. MK-2206 is an AKT pathway inhibitor that has shown promise in phase I testing in advanced solid tumors (ASCO 2009 abstract 3503).

TOPIC INDEX

Cancer Types
Breast Breast (HER2+) Breast (Triple-Negative) CML Colorectal Gastrointestinal GIST Genitourinary Gynecologic Head & Neck	Hematology Kidney (Renal Cell) Leukemia Lung Lymphoma Melanoma Multiple Myeloma Ovarian Prostate Sarcoma
Supportive Care	More Topics
Bone Metastases End-of-Life Care Palliative Care	Ethics in Oncology Practice Management Practice & Policy

All Topics

FROM PHYSICIANS PRACTICE

Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.

Improving Care Coordination in Your Practice
Susanne Madden, June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.

Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler, June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.

Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate, June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.

iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.

Astra Zeneca and Merck partner on drug regimen

Join the Conversation